Metastatic carcinoma of unknown primary: complete response to second-line treatment with plicamycin.
In selected groups of patients, metastatic carcinoma of unknown primary (MCUP) is highly responsive to cisplatin-based combination chemotherapy. These therapeutic responses usually are partial and shortlived. The authors report the case of a 41-year-old man whose MCUP relapsed after responding to cisplatin, bleomycin, and etoposide. Alternate-day treatment with plicamycin induced a second complete remission (CR) in this patient with minimal hematologic and metabolic toxicity. Plicamycin may prove effective in enhancing CR rate, prolonging CR duration, and salvaging cisplatin failures in MCUP.
Hescock
H
H
Hematology-Oncology Section, Medical Service, Bay Pines VA Medical Center, Florida 33504.
Parker
M
M
Wang
T Y
TY
Ballinger
R
R
Balducci
L
L
D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D008297:Male; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging / Q000473:pathology; D008926:Plicamycin / Q000627:therapeutic use*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
D008926:Plicamycin